Vascularendothelialgrowthfactor-165(VEGF-165)isahomodimericglycoproteinconsistingoftwodomains:aheparin-bindingdomainandareceptor-bindingdomain.AtleastfivedifferentVEGFisoforms(VEGF-121,VEGF-145,VEGF-165,VEGF-189,VEGF-206)areknowninhumans,allofwhicharederivedbyalternativesplicingofVEGFmRNA,butdifferintheirsecretionandheparin-bindingproperties.AmongVEGFisoforms,VEGF-165isthemostcommonandBIOLOGicallyactive.Itisanendothelial,cell-specific,andangiogenicgrowthfactorthatisapotentvascularpermeABIlityfactor.VEGF-165isreleasedbymanycellpopulations,includingfibroblasts,monocytes,macrophagesandlymphocytes.VEGF-165inducesvesseldilationbyreleasingnitricoxideandcanhaveachemotacticimpactonothergrowth-promotingcellpopulations.VEGF-165synthesisisstimulatedmoststronglybythelackofoxygen,aneffectthatistranslatedbyhypoxiasensitivetranscriptionfactor,HIF1.RecombinanthumanVEGF-165isanon-glycosylatedhomodimer,containingtwo165aminoacids,withatotalmolecularweightof38.2kDa(2-5).

•AccessionNumber:P15692-4•Synonyms:VEGF-A,VPF,glioma-derivedendothelialcellmitogen•Purity:≥95%purity.DeterminedbyHPLC,reducingandnon-reducingSDS-PAGE,UVspectroscopyat280nm.•Bioactivity:ED50isdeterminedbydose-dependentproliferationofHUVECsTheED50istypicallylessthan5ng/mL.•Animalcomponent-freeandcarrier-free•Custompackagingavailable

Forresearchorfurthermanufacturinguseonly.

Alsoavailableinothersizes.